Watch: Biotech Going Up Against Big Pharma
As co-founder, chairman & chief executive of Ocugen, Shankar Musunuri, is looking to bring eye disease products to the patients that big pharma’s drugs have left out. The Malvern, Penn.-based company has four compounds in its pipeline at various stages of development. It’s most advanced candidate, OCU300, is gearing up for Phase III trials in 2018. It’s second candidate, OCU310, combines brimonidine, a drug usually designed for patients with glaucoma, and a steroid. With some of Ocugen’s products, like it’s OCU100 compound designed to delay the progression of retinitis pigmentosa, there is no other drug currently on the market – so there’s no immediate competition. “The goal is to get something to the market to help patients as soon as possible because they don’t have anything today,”
Latest
Super Bowl LVII Ad Spots Sold Out. Why Did It Take So Long This Year?
Patrick Rishe, Host of “Suite Talk: The Business Behind Sports“, takes a look at the 2023 Super Bowl ad trends. An uncertain economy is one of the biggest factors as to why it took companies so long to buy out the ad spaces for this year’s Super Bowl. Not to mention we have seen nothing […]
Thoughts About Pro AV’s Path Forward in ’23
Can we take a second and acknowledge how impactful Gina Sansivero and Brandy Alvarado-Miranda are for our industry? … I had a chance to sit down with BOTH of them to break down some of the hottest trends from ISE this year, but also to dive deeper into the conversations and challenges that are […]
How Have Home Intelligence and Automated Shading Solutions Improved Home Energy Efficiency and Comfort?
On today’s episode of the Draper at Home podcast, host Michelle Dawn Mooney, speaks with Scotty Allen, the Chief Operating Officer of Josh.ai, Maryellen Oswald, Custom Integration & Partnerships Channel Manager, Somfy USA, and Tyson McDonald, Director of Business Development, Motorized Solar Solutions for Draper, Inc., to talk about how the effect of home intelligence […]
